The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Travel
  • Financial
  • Services
  • Construction

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Waarom brand mentions in ChatGPT steeds belangrijker worden
  • The Stork Foundation Announces 2025 Year-End Impact and Grant Awards Amid Rising National Demand
  • Pawprint Oxygen Turns Pet Safety Viral With "Pets Live Here" Window Decals — Helping First Responders Save Lives
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Rande Vick Introduces Radical Value, Challenging How Brands Measure Long-Term Value
  • Lisa Mauretti Launches Peace of Mind Travel Coaching to Guide Fearful Travelers to Discover the World with Confidence
  • New Year, New Home: Begin 2026 at Heritage at South Brunswick
  • Food Journal Magazine Releases Its 'Best Food In Los Angeles Dining' Editorial Section
  • Enders Capital: 25% Gains with Just -0.80% Maximum Monthly Drawdown in Volatile Debut Year 2025

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Vent Pros Expands Operations into Arizona to Meet Growing Demand for Commercial Ventilation and Kitchen Hood Cleaning Services
  • Klein Civil Rights Expands with New Offices in New York's Historic Woolworth Building
  • Biz Hub Financial Hosts 9th Annual Client Appreciation Event, Awards $1,000 CARES Community Grant
  • Green Office Partner Appoints Aaron Smith as Chief Revenue and Growth Officer
  • A Family Completes a Full Circumnavigation of the Globe in a Self-Contained Camper Van
  • Former Google Search Team Member Launches AI-Powered SEO Consultancy in Las Vegas
  • Q3 2025 Arizona Technology Industry Impact Report Highlights Shifting Job Demand, Semiconductor Momentum and Workforce Investment
  • $6.4 Million Purchase of Construction Vehicles Plus New Dealership Agreement with Cycle & Carriage for Heavy Equipment Provider to Singapore Region
  • Acmeware and Avo Partner to Bring Real-Time Data Integration to MEDITECH Customers
  • CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
  • Talented Learning Unveils 2026 "Office Hours for LMS Buyers" Webinar Series
  • New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year
  • Bargeld Financial Launches Professional, Affordable Tax Preparation Services for the 2026 Tax Season
  • International Law Group Expands Emergency Immigration Consultations for Somali Minnesotans Amid ICE Actions
  • Premium Bail Bonds Proudly Sponsors BOFAB BBQ Team at the 2026 Lakeland Pigfest
  • UK Financial Ltd Receives Recognition In Platinum Crypto Academy's "Cryptonaire Weekly"
  • Nell Tice Empowers Small Businesses Through Strategic Video Production
  • P-Wave Press Announces Pushing the Wave 2024 by L.A. Davenport
  • Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District

Popular on PennZone

  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 276
  • Neurosurgeon Chengyuan Wu, MD, MSBmE, Joins the Actuated Medical Advisory Board - 156
  • Children Rising Appoints Marshelle A. Wilburn as New Executive Director
  • NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
  • Bent Danholm Joins The American Dream TV as Central Florida Host
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • Top Tips for Hiring HVAC Contractors in Philadelphia
  • Allegiant Management Group Named 2025 Market Leader in Orlando by PropertyManagement.com
  • Nonprofit Operations' First-Of-Its-Kind Job Portal Empowers Nonprofit Job Seekers
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education

Similar on PennZone

  • AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us